Metabolic Peptides

Cagri vs GLP-1S

Cagri and GLP-1S act on entirely different receptor systems. Cagri is a long-acting amylin analog, while GLP-1S is a GLP-1 receptor agonist. The two are frequently studied together because their mechanisms are complementary.

Side-by-Side Comparison

PropertyCagriGLP-1S
CategoryLong-acting amylin analog (dual amylin/calcitonin receptor agonist)GLP-1 receptor agonist
Mechanism of ActionActivates amylin and calcitonin receptors; used to study amylin receptor signaling and receptor activity-modifying protein (RAMP) complexesActivates the GLP-1 receptor; raises intracellular cAMP in receptor-expressing cell lines
Molecular Weight~4,409 Da (lipidated amylin analog)~4,113 Da
Research FocusAmylin/calcitonin receptor signaling, combination assays with GLP-1 receptor agonistsGLP-1 receptor-selective signaling assays
Receptor TargetAmylin receptors (AMY1-3) + calcitonin receptorGLP-1 receptor (selective)
Half-Life~7-8 days (lipidation enables albumin binding)~7 days (C-18 fatty diacid, albumin binding)

Key Differences

  • Cagri mimics amylin, a pancreatic beta-cell hormone co-secreted with insulin; GLP-1S mimics GLP-1, an intestinal incretin hormone. They engage separate receptor families.
  • Cagri signals through amylin and calcitonin receptor complexes; GLP-1S signals through the GLP-1 receptor alone.
  • Both are lipidated peptides with albumin-binding modifications and roughly week-long half-lives.
  • Because the receptor families are independent, the two are typically studied in combination (see Cagri-Sema) rather than head-to-head.

Research Summary

Cagri and GLP-1S target two independent receptor systems: the amylin/calcitonin receptor family and the GLP-1 receptor. Both are lipidated peptides with roughly week-long half-lives. Rather than direct competitors, they are best understood as complementary tools; combination research (Cagri-Sema) explores how simultaneous engagement of the two receptor systems behaves in cell-based assays.

What is the difference between Cagri and GLP-1S?

Cagri is a long-acting amylin analog that signals through amylin and calcitonin receptors, while GLP-1S is a GLP-1 receptor agonist. Both have ~7-day half-lives. They engage independent receptor systems, and combination research (Cagri-Sema) studies how the two behave together in assay models.

Disclaimer: All compounds referenced on this page are sold for research and laboratory use only. The comparisons presented are based on published scientific literature and are intended for educational and informational purposes. This content does not constitute medical advice. Researchers should consult primary literature and applicable regulations before designing study protocols.